Cerchione Claudio, Nappi Davide, Romano Alessandra, Martinelli Giovanni
Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
Department of Hematology and Cell Bone Marrow Transplantation (CBMT), Ospedale Centrale di Bolzano, 39100 Bolzano, Italy.
Cancers (Basel). 2022 Aug 23;14(17):4063. doi: 10.3390/cancers14174063.
Neutropenia and febrile neutropenia are common and potentially life-threating events associated with chemotherapy treatment in Hodgkin lymphoma (HL). Neutropenia-related infectious events could be an issue both for direct clinical consequences and for delay in treatment delivery, affecting final outcomes in a potentially highly curable disease. Pegfilgrastim is the pegylated form of filgrastim, the recombinant form of human G-CSF, capable of prevent and mitigate neutropenic effects of chemotherapy, when adopted as primary prophylaxis in several hematological malignancies. No updated version of major international guidelines provides clear indication on prophylaxis use of pegfilgrastim in HL to prevent febrile neutropenia episodes in HL. Moreover, to date, scarce and non-uniform clinical experiences evaluating pegfilgrastim as prophylaxis in HL are present in the literature. Herein, we propose a brief summary of the literature data about efficacy and safety of the use of pegfilgrastim as primary prophylaxis in HL during chemotherapy treatment.
中性粒细胞减少症和发热性中性粒细胞减少症是霍奇金淋巴瘤（HL）化疗治疗中常见且可能危及生命的事件。与中性粒细胞减少相关的感染事件可能会引发直接的临床后果以及治疗延迟问题，从而影响这种具有高度治愈潜力疾病的最终治疗结果。培非格司亭是重组人粒细胞集落刺激因子（G-CSF）的聚乙二醇化形式，在多种血液系统恶性肿瘤中作为主要预防措施使用时，能够预防和减轻化疗引起的中性粒细胞减少效应。目前尚无主要国际指南的更新版本对HL患者预防性使用培非格司亭以预防发热性中性粒细胞减少发作给出明确建议。此外，迄今为止，文献中关于在HL中评估培非格司亭作为预防措施的临床经验稀缺且不统一。在此，我们简要总结一下关于培非格司亭在HL化疗治疗期间作为主要预防措施使用的疗效和安全性的文献数据。
